Related Experiment Video
Updated: May 27, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Triple-negative breast cancer molecular subtypes and potential detection targets for biological therapy indications
Yanchuan Zhang1,2, Qinghua Li1,2, Jie Lan3
1Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chengdu, China.
Abstract:
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer associated with poor prognosis. While chemotherapy remains the conventional treatment approach, its efficacy is limited and often accompanied by significant toxicity. Advances in precision-targeted therapies have expanded treatment options for TNBC, including immunotherapy, poly (ADP-ribose) polymerase inhibitors, androgen receptor inhibitors, cell cycle-dependent kinase inhibitors, and signaling pathway inhibitors. However, the heterogeneous nature of TNBC contributes to variations in treatment outcomes, underscoring the importance of identifying intrinsic molecular subtypes for personalized therapy. Additionally, due to patient-specific variability, the therapeutic response to targeted treatments is inconsistent. This highlights the need to strategize patients based on potential therapeutic targets for targeted drugs to optimize treatment strategies. This review summarizes the classification strategies and immunohistochemical (IHC) biomarkers for TNBC subtypes, along with potential targets for identifying indications for targeted drug therapy. These insights aim to support the development of personalized treatment approaches for TNBC patients.
Insights
Triple-negative breast cancer (TNBC) is aggressive, with limited chemotherapy options. Identifying molecular subtypes and biomarkers is crucial for personalized targeted therapies and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Precision Medicine
Background:
- Triple-negative breast cancer (TNBC) presents a significant clinical challenge due to its aggressive nature and poor prognosis.
- Conventional chemotherapy for TNBC offers limited efficacy and substantial toxicity.
- Emerging targeted therapies offer new avenues, but treatment response varies due to TNBC's inherent heterogeneity.
Purpose of the Study:
- To review classification strategies for TNBC molecular subtypes.
- To identify immunohistochemical (IHC) biomarkers for TNBC subtyping.
- To explore potential therapeutic targets for personalized drug therapy in TNBC.
Main Methods:
- Literature review of TNBC classification systems.
- Analysis of immunohistochemical (IHC) biomarkers associated with TNBC subtypes.
- Identification of actionable therapeutic targets for precision medicine approaches.
Main Results:
- TNBC exhibits significant molecular heterogeneity, necessitating subtype classification for effective treatment.
- Specific IHC biomarkers can aid in distinguishing TNBC subtypes.
- Various targeted therapies, including immunotherapy and pathway inhibitors, show promise but require patient stratification.
Conclusions:
- Personalized treatment strategies for TNBC are essential, driven by molecular subtyping and biomarker identification.
- Understanding TNBC heterogeneity is key to optimizing the use of targeted therapies.
- This review provides insights into IHC biomarkers and therapeutic targets to guide personalized TNBC treatment.
